Close

Drug Research

Singapore To Be Home To $1.5bn AstraZeneca Production Plant

On May 20, 2024, AstraZeneca, the global biopharma company, announced plans to build a $1.5 billion manufacturing facility in Singapore. With this announcement, the...

Laboratory-Developed Tests Set To Be Regulated By The FDA

The FDA’s final rule that solidifies its presence and authority on Laboratory-Developed Tests- LDTs goes on to mark a prominent shift in the regulation...

AbbVie, Gilgamesh Pharma Partner on Next-Gen Psychiatric Therapies

AbbVie and Gilgamesh Pharmaceuticals entered a collaboration and option-to-license agreement to develop next-generation therapies for psychiatric disorders. This collaboration will leverage AbbVie's expertise in...

Fulcrum Enters Collaboration & License Agreement with Sanofi

Fulcrum Therapeutics Inc., a clinical-stage biopharmaceutical company focused on developing small molecules, has entered into a collaboration and license agreement with Sanofi for the...

Aldevron, Acuitas Partner to Expand Capabilities in mRNA LNP Encapsulation

Aldevron, a global manufacturer of DNA, RNA, and proteins used in cell and gene therapies and vaccine development, has entered a strategic partnership with...

Abzena Launches EpiScreen 2.0, a Next Generation Immunogenicity Tool for De-Risking the Development of Complex Biologics and Bioconjugates

Abzena, the leading end-to-end integrated CDMO for complex biologics and bioconjugates, has announced the launch of its enhanced bioassay platform EpiScreen® 2.0, a comprehensive suite of...

ChargePoint to expand product range by investing in a dedicated multi-million-pound single-use manufacturing facility

ChargePoint Technology, a specialist in powder and liquid transfer, has invested in a new manufacturing facility dedicated to its single-use products in Speke, Liverpool,...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Must read